Chengdu Lingtai Krypton Biotechnology

Chengdu Lingtai Krypton Biotechnology (lncTAC), founded in 2021, is a clinical-stage biotechnology company focused on developing innovative nucleic acid drugs based on long non-coding RNA (lncRNA). The company's name, lncTAC, is an acronym for its core "lncRNA-based Targeting Chimera" technology platform.

The founding team combines deep scientific expertise with extensive pharmaceutical industry experience. Founder and Chairman, Professor Xu Song, is a pioneering scientist in the lncRNA field with 20 years of research experience, a PhD from Peking Union Medical College, and postdoctoral work at Yale University. He is joined by co-founder and CEO, Dr. Lihua Ding, who brings over 30 years of senior management experience from multinational and domestic pharmaceutical companies, and co-founder Professor Chong Qin, an expert in PROTAC and one of the inventors of the lncTAC® technology.

The company has developed two core proprietary technology platforms: lncTAC® and UNAST®. The lncTAC® platform utilizes lncRNA-mediated targeting chimera technology to address previously "undruggable" targets. The UNAST® platform was created to solve the critical challenges of nucleic acid drug instability and delivery. Together, these platforms form the foundation for a rich pipeline of over 20 innovative products. These drug candidates target a range of refractory diseases, including cardiovascular and cerebrovascular diseases, neurodegenerative conditions like Alzheimer's and Parkinson's, and various cancers such as pancreatic, lung, and colorectal cancer.

LncTAC's business model focuses on research and development, with a commercialization strategy centered on out-licensing and forming in-depth collaborations with domestic and multinational corporations for market development. The company has successfully raised significant capital, including a Pre-A round of ¥100 million in August 2023, to advance its pipeline through preclinical stages and expand its research teams.

Keywords: lncRNA, nucleic acid drugs, drug development, biotechnology, targeting chimera technology, UNAST, lncTAC, undruggable targets, preclinical, oncology, neurodegenerative diseases, cardiovascular diseases, gene therapy, RNA therapeutics, drug delivery, pharmaceutical, clinical-stage, nucleic acid stability, innovative therapies, molecular biology